23 publications
Name | Date | Type | Actions |
---|---|---|---|
2008 annual earnings The Vétoquinol Board of Directors, meeting on March 20, 2009, reviewed the group’s business and approved the group’s 2008 financial statements. |
31/03/2009 | Public releases | |
2008 revenue: €234.4 M Revenue grew in 2008, despite poor economic conditions in the second half and |
22/01/2009 | Public releases | |
2009 Revenue improvement in trends in the first quarter Vétoquinol’s revenue for the first quarter of 2009 reached €57.1 M, an increase of 4.4% over the first quarter of 2008. |
09/04/2009 | Public releases | |
2010 annual earnings Lure (France), April 4, 2011 – Vétoquinol’s Board of Directors, meeting on March 18, 2011, has reviewed the Group’s business and approved its 2010 financial statements. |
04/04/2011 | Public releases | |
2010 Revenues grow 11.8%, driven by organic growth The Vétoquinol Group reports sustained sales growth driven by its “hybrid” business model, supported by a sound level of organic growth. |
25/01/2011 | Public releases | |
European launch of new Nsaid Cimalgex® Lure (France), June 14, 2011 – Vetoquinol announces the European launch of CIMALGEX®, a new treatment for pain and inflammation in dogs. |
14/06/2011 | Public releases | |
Forcyl®: european launch of new drug Lure (France), September 29, 2011 – Vétoquinol announces the European launch of Forcyl®, a new drug based on 16% concentrated marbofloxacin allowing the treatment of cattle respiratory infections with a single injection. |
29/09/2011 | Public releases | |
Growth in Revenues in the first half of 2009 Vétoquinol’s revenues in the first half of 2009 totalled EUR 119.9 million, an increase of 2.7% compared to the first half of the preceding year. |
16/07/2009 | Public releases | |
Information relative à un engagement du Conseil d’Administration pris au bénéfice du Directeur Général Délégué Groupe (french) Lors de sa réunion du 13 mars 2009, le Conseil d’Administration a pris l’engagement, dans le cadre de la loi du 21 août 2007, de verser une indemnité à Monsieur Dominique HENRYON, Directeur Général Délégué Groupe, en cas de révocation de ce dernier pour tout autre motif qu’une faute grave. Cette décision se substitue à celle du 1er décembre 1998. |
30/03/2009 | Public releases | |
International expansion and new product launches Lure (France), July 19, 2011 – Vétoquinol Group sales rose to €139.7 million in the first six months of 2011. |
19/07/2011 | Public releases |